Haemonetics Corporation

Haemonetics Corporation

HAENYSE / NASDAQHealthcareSmall cap

$120.16-$0.21 (-0.2%)

Last close · Data as of Nov 20, 2026

Market cap
$3.2B
P/E
32.6x
EV / EBITDA
15.5x
Revenue
$1.3B
Net margin
7.3%
ROCE
11.4%

+60.0% over the last year

Haemonetics Corporation price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+1.6%
3M
+11.0%
6M
+101.7%
1Y
+60.0%
5Y
+113.9%

52-week range

Day change -$0.21 (-0.2%) from $120 to $120 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in HAE, bought on each weekday since 2021.

News & filings

What Haemonetics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthThe price is 45.4% above its 200-day average, and the 50-day average is above the 200-day.

Concerns (1)

  • Return on equity fell from 20.4% to 12.2% between fiscal 2025 and fiscal 2026.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2026

Rule-based from financial data. Not advice.

About the company

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally.

Read moreShow less

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Shares outstanding
45.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$3.2B
P/E
32.6x
P/B
4.0x
EV / EBITDA
15.5x
EV / Sales
3.1x
P/S
2.4x
52-week high
$127.42
52-week low
$52.24

Profitability

Operating margin
18.1%
Net margin
7.3%
EBITDA margin
20.1%
ROE
12.2%
ROCE
11.4%
ROIC
10.1%
ROA
4.1%
Asset turnover
0.56

Growth

Revenue
$1.3B
Revenue growth, 1Y
-2.0%
Revenue CAGR, 3Y
4.5%
Net profit growth, 1Y
-42.0%
Free cash flow
$260.4M

Solvency

Current ratio
2.95
Debt / Equity
1.54
Debt / Assets
0.51
CFO / Net profit
3.01
Cash / Market cap
7.7%

Where the revenue went

Of every $100 of FY2026 revenue, $7 was left as net income.

Haemonetics Corporation income statement flow, FY2026
Haemonetics Corporation income statement flow, FY2026: flows
FromToAmount
RevenueCost of revenue$546.4M
RevenueGross profit$787.6M
Gross profitResearch and development$59.8M
Gross profitSelling, general and administrative$442.4M
Gross profitOther operating expenses$44.0M
Gross profitOperating income$241.4M
Operating incomePretax income$128.0M
Operating incomeInterest and other expense$113.4M
Pretax incomeTax and other$30.7M
Pretax incomeNet income$97.3M

Revenue and net profit

Revenue fell 2.0% in FY2026; net profit is the dashed line.

Haemonetics Corporation revenue and net profit by fiscal year
Haemonetics Corporation revenue and net profit by fiscal year
DateRevenueNet profit
FY2023$1.2B$115.4M
FY2024$1.3B$117.6M
FY2025$1.4B$167.7M
FY2026$1.3B$97.3M

Cash flows

FY2026: $293.2M from operations, $260.4M free after investment (dashed).

Haemonetics Corporation operating and free cash flow by fiscal year
Haemonetics Corporation operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2023$273.1M$81.7M
FY2024$181.8M$143.6M
FY2025$181.7M$142.4M
FY2026$293.2M$260.4M

Growth

Latest fiscal year 2026: each figure with its change over the year before.

Revenue
$1.3B-2.0%1Y
EBITDA
$268.5M-20.4%1Y
Net profit
$97.3M-42.0%1Y
Cash from operations
$293.2M+61.4%1Y
Free cash flow
$260.4M+82.8%1Y
Revenue CAGR, 3Y
4.5%
Net profit CAGR, 3Y
-5.5%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2026$1.3B$268.5M$97.3M$260.4M12.2%-2.0%-42.0%

Monthly returns

Month-by-month returns of HAE across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2026.

LineFY2026
Assets$2.4B
Liabilities$1.6B
Equity$796.3M
Paid-in capital$554.1M
Retained earnings$279.3M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; HAE highlighted.

P/E against peers

HAE trades at 32.6x earnings against a peer median of -6.8x.

  1. Haemonetics Corporation (this company)32.6x

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Denali Therapeutics Inc., Dyne Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Haemonetics CorporationHAEthis company$3.2B32.6x4.0x12.2%15.5x
Beam Therapeutics Inc.BEAM$3.4B-42.2x2.7x-6.5%-9.0x
Tango Therapeutics, Inc.TNGX$3.2B-31.5x9.3x-29.3%-28.7x
Denali Therapeutics Inc.DNLI$3.2B-6.2x3.2x-50.6%-5.6x
Relay Therapeutics, Inc.RLAY$3.2B-11.5x5.6x-48.8%-10.4x
Option Care Health, Inc.OPCH$3.2B15.2x2.4x15.6%10.3x
Alignment Healthcare, Inc.ALHC$3.1B—17.4x-0.4%62.7x
Dyne Therapeutics, Inc.DYN$3.0B-6.8x3.1x-45.9%-5.3x
Warby Parker Inc.WRBY$3.0B1803.7x8.0x0.4%64.7x
Peer median—-6.8x4.4x-17.9%-5.4x

Year-to-date ROI

HAE since 1 January, against earlier years.

Historical volatility

HAE's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Haemonetics Corporation operating margin by fiscal year
Haemonetics Corporation operating margin by fiscal year
DateOperating margin
FY202313.3%
FY202413.4%
FY202514.8%
FY202618.1%
LineFY2026
Cost of revenueCost Of Revenue$546.4M
Gross profitGross Profit$787.6M
Operating expensesOperating Expense$546.2M
Research and developmentResearch And Development$59.8M
Selling, general and administrativeSelling General And Administration$442.4M
Depreciation and amortisationDepreciation And Amortization In Income Statement$44.0M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$44.0M
Amortization$44.0M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$44.0M
Total expensesTotal Expenses$1.1B
Pretax incomePretax Income$128.0M

Learn while you research

Academy chapters picked for Haemonetics Corporation and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 32.6, learn when high multiples are justified.6 min read
  3. 03 Leverage RatiosDebt/Equity of 1.54 is elevated, understand what that means for solvency.6 min read
  4. 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  5. 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  6. 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
Browse the full Equiscale Academy →